At the news
? MIXEDIMPACT 6/10 8-K filed Feb 25, 2026 at 16:30 ET
Chemed Corp reported flat Q4 2025 revenue of $639.3 million but a 9% decline in GAAP EPS to $5.48. The VITAS segment showed modest growth in net patient revenue (1.9%) and admissions (6%), while Roto-Rooter revenue declined 3.7%. The company provided strong 2026 guidance with EPS expected to grow to $23.25-$24.25, driven by a significant reduction in Medicare Cap billing limitations and projected revenue growth across both segments.
- Q4 2025 revenue was $639.3 million, essentially flat YoY
- GAAP EPS was $5.48, down 9% YoY; Adjusted EPS was $6.42, down 6% YoY
- VITAS net patient revenue increased 1.9% to $418.8 million with 6% growth in admissions
- Roto-Rooter revenue decreased 3.7% to $220.6 million with significant margin compression
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access